Latest News and Press Releases

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Bladder cancer is one of the most common, and most overlooked, cancers in the United States, impacting hundreds of thousands of families each year. This...

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry

An update on corporate progress and reported third quarter financial results as of March 31, 2026 (Year end June 30).

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited...

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for...

AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and...

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or...

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cellsCorrelation established between EO2463-induced and B cell...